also requires experience and a special interest, not exceptional qualities. All these requirements are readily available, with a little effort and positive motivation.
Medicine is a dynamic subject; the patients in our care surely deserve the time it takes to address critically the alternative approaches to patient management and review traditional procedures. The time has come for clinicians and cytologists alike to debate the advantages and disadvantages of a more flexible and sympathetic approach to the management of gynaecological problems, with an honest appraisal of the true worth and application of current alternative methods of diagnosis.
Anne 
Antiviral treatment of chronic hepatitis B virus infection
There are probably more than 175 million carriers of the hepatitis B virus (HBV) in the world today. These individuals are at risk of developing chronic hepatitis, cirrhosis, and primary liver cell carcinoma. An effective treatment of HBV infection and its associated liver disease is therefore urgently needed. Although antiviral therapy for chronic HBV infection is not yet available for general clinical use, several promising compounds have been identified which possess specific activity against HBV in man. There are two phases of chronic HBV infection. In the first, there is active viral replication with high-titre hepatitis B surface antigen (HBsAg). Hepatitis B e antigen (HBeAg), HBV-DNA, and DNA polymerase are present in the serum, which, along with other body fluids, is infectious. Serum transaminases tend to be elevated, and hepatic histology reveals an active inflammatory lesion. After a variable length of time, usually several years, the patient enters the second phase in which viral replication ceases. The patient has now lost HBeAg and has developed hepatitis B e antibody (anti-HBe). HBV-DNA and DNA polymerase are no longer detectable in the serum but HBsAg continues to be secreted by clones of hepatocytes containing integrated hepatitis B viral DNA (Fowler et al. 1984) . Serum transaminase tends to normalize, and the level of inflammatory necrosis of hepatocytes subsides.
The aim of therapy of chronic HBV infection is to eradicate the virus in both its replicating and non-replicating forms, thereby preventing the development of progressive liver disease and liver cell cancer. The approach to therapy will therefore be dependent on the phase of the infection (HBeAgor anti-HBe-positive). Since HBeAg-positive patients have an active liver disease and are infectious, they stand to derive the greatest benefit from antiviral therapy. In this group, the goal of therapy is a permanent inhibition of HBV replication. This will be reflected serologically by loss of serum HBV-DNA and DNA polymerase, seroconversion from HBeAg to anti-HBe, and decrease in HBsAg titre. These changes are associated with an initial rise and subsequent normalization of serum transaminases, reduction of inflammatory activity in the liver, and decreased infectivity of the patient. If treatment is instituted before stable clones of hepatocytes with integrated hepatitis B viral DNA are established, the patient may also lose HBsAg and HBV will thus be completely eradicated.
Interferon, adenine arabinoside (ARA-A) and its monophosphate (ARA-AMP), and acycloguanosine (acyclovir) are the most promising drugs for treatment of active HBV replication. Interferons are polypeptides which are produced in response to virus infection and 0141-0768/84/120998-04/$O 1.00/0 g 1984 The Royal Society of Medicine induce an antiviral state in non-infected cells. The antiviral mechanism of interferon is complex. Apart from inhibition of viral RNA and protein synthesis, it can also induce changes in the host cells and act as an immunomodulating agent enhancing host immune responsiveness. There are three main types of interferonalpha, beta, and gamma. Initially, interferons were produced by stimulation of cell lines with either viruses or synthetic polynucleotides. Genetic engineering has allowed the insertion of alpha-and betainterferon genes into various bacteria or yeasts which then produce large amounts of the protein.
Much of the current research is being conducted with interferons which are a mixture of polypeptides produced from either normal leukocytes or lymphoblastoid cell lines, but future work may be undertaken with the genetically-engineered interferons which are homogeneous single proteins (Smith et al. 1983 ).
Human leukocyte interferon, an alphainterferon, has been used either alone or in combination with ARA-A to treat chronic HBV infection (Scullard et al. 1981) . In these studies, 37% of patients lost HBeAg and DNA polymerase activity and seroconverted to anti-HBe, and a few patients also cleared HBsAg. These changes in viral markers were accompanied by improvements in symptoms, biochemistry and histology. Since two drugs were used, it is not clear whether human leukocyte interferon or ARA-A, or both, were responsible for these beneficial effects. A controlled study using human leukocyte interferon alone at a much lower total dose failed to show any long-term inhibition of viral replication (Weimar et al. 1980) . Controlled studies are still required with more protracted and higher-dose regimens of this type of interferon.
Lymphoblastoid interferon, another alphainterferon, is a mixture of at least eight polypeptides. Studies at the Royal Free Hospital using daily intramuscular injections or intravenous infusions of lymphoblastoid interferon for one month have shown that HBV replication is suppressed during administration of the drug (Weller et al. 1982c) . Further studies indicate that thrice-weekly injections are as effective as the daily regimen in suppressing HBV replication and are better tolerated . Two largescale studies of lymphoblastoid interferon are currently in progress, and it is clear that some patients have developed permanent inhibition of HBV replication (Novick et al. 1984a ). Side effects, most notably a 'flu-like syndrome', do occur, but tolerance usually develops rapidly.
Fibroblast (beta) interferon has been shown to have no significant antiviral activity in chronic HBV infection (Weimar et al. 1979) . This lack of effect may be related to the greater instability and decreased bioavailability of this compound, and further studies are needed. Gamma-interferons have, not yet been produced in sufficient quantities to be evaluated, but there is great interest in them because they may possess more potent immunomodulatory effects than other interferons (Dolei et al. 1983 ).
ARA-A is a synthetic purine nucleoside with a broad spectrum of antiviral activity against DNA viruses. Early uncontrolled studies indicated that ARA-A has activity against HBV (Chadwick et al. 1978) . In a randomized, controlled study of ARA-A at the Royal Free Hospital, 4 of 7 treated HBeAg positive patients lost DNA polymerase activity (Bassendine et al. 1981) . In 3 of these, HBeAg disappeared and levels of HBsAg and serum transaminase decreased. No such changes occurred in the control group.
Although ARA-A has a low toxicity relative to other antiviral agents, its usefulness is limited by insolubility and the need for continuous intravenous administration. ARA-AMP, the synthetic ester of ARA-A, is at least 400 times more water soluble and can be given by twice-daily intramuscular injection. In 5 patients given a short course of ARA-AMP at a dosage of 10 or 15 mg/kg/day, HBV replication was suppressed transiently in all and thrombocytopenia occurred in 2 (Weller et al. 1982a ). In 3 further consecutive patients given a longer course (21-34 days) with 5 mg/kg/day after five days of the higher dose, thrombocytopenia was not seen and inhibition of viral replication was permanent. These patients seroconverted from HBeAg to anti-HBe, and DNA polymerase and HBV-DNA became undetectable. More protracted therapeutic regimens are now being examined but appear to be limited by development of a severe but reversible sensory polyneuropathy.
Acycloguanosine inhibits herpes simplex virus replication in vitro and in vivo, its action being dependent on phosphorylation of the drug by a virus-coded thymidine kinase (Fyfe et al. 1978) . In vitro studies have also shown activity against cytomegalovirus and Epstein-Barr viruses but at much higher drug concentrations. These DNA viruses, like HBV, lack the virus-coded thymidine kinase. Recently, acycloguanosine has also been shown to inhibit HBV replication in vivo (Weller et al. 1983a) . Extreme care must be taken in patients with pre-existing renal impairment or dehydration, as nephrotoxicity may develop.
Further studies in chronic HBV infection are needed to establish a suitable regimen.
Once the patient has ceased to replicate the virus (anti-HBe-positive phase), the level of inflammatory necrosis of hepatocytes usually subsides and no therapy is necessary. If the patient has already developed cirrhosis by the time viral replication has ceased, there is a significant risk of development of primary liver cell cancer, presumably because of the presence of clones of cells containing integrated HBV-DNA (Thomas 1983). If inflammatory necrosis continues in an anti-HBe-positive patient, coexistent infection with the hepatitis D virus (HDV; formerly known as the delta agent) should be strongly suspected. HDV is a defective RNA virus which can replicate only in the presence of HBV (Rizzetto 1983 ). HDV was first described in the south of Italy, where it is endemic, but it has now been shown to be prevalent amongst Northern European haemo-Ohiliacs and drug addicts with chronic HBV infection (Weller et al. 1983b ). Patients with persistent infection with HDV and HBV have chronic liver disease which is rapidly progressive and more severe than would be expected on the basis of chronic HBV infection alone.
Rarely, a patient with anti-HBe and chronic active liver disease who does not have concomitant HDV infection will be seen. Such patients may have continuing HBV replication manifested by the presence of hepatitis B core antigen (HBcAg) in liver cell nuclei , and antiviral therapy may be indicated. A suitable period of observation, probably one year, is necessary in this circumstance to be sure that such patients have not recently seroconverted from HBeAg to anti-HBe, in which case the hepatic histology may yet improve. Another small group of anti-HBe-positive patients without HDV infection will have continuing inflammatory necrosis without detectable HBcAg display in the liver. These are likely to have an autoimmune attack initiated by a previous period of HBV replication (Eddleston & Williams 1974, Thomas et al. 1982 ) and, again after a period of careful monitoring, may respond to moderate doses of prednisolone (Weller et al. 1982b ).
Several problems remain in the search for a suitable regimen of antiviral therapy in chronic HBV infection. It is clear that some patients respond to treatment while others do not. In order to identify pretreatment factors which influence responsiveness, we reviewed the clinical features of 38 male HBeAg-positive patients who had received ARA-A, ARA-AMP, or lymphoblastoid interferon at the Royal Free Hospital between 1977 and 1982 (Novick et al. 1984b ). All of these patients had been followed for one year or longer. The major finding of this analysis was that only 2 of 19 (11%) homosexual men had had a favourable response, defined as loss of HBeAg and HBV-DNA, as compared with 10 of 19 (53%) heterosexual men. This difference between reponsiveness in homosexual and heterosexual men is highly significant and may be related to more severe immunological abnormalities in the homosexual group. Serum transaminase levels were also higher in responders, a finding also noted by investigators from the USA (Scullard et al. 1981) . Of note, both homosexual responders had received lymphoblastoid interferon; none of 13 homosexual men but 8 of 16 heterosexual men responded to ARA-A or ARA-AMP. These observations are particularly relevant to studies of antiviral therapy in Northern Europe and the USA, where a large proportion of patients with chronic HBV infection will be homosexual men.
In evaluating drugs which induce seroconversion from HBeAg to anti-HBe, it must be recognized that these events do occur spontaneously. In males, sexual preference appears to be a major factor which influences the spontaneous seroconversion rate. In a study of 100 consecutive British HBsAg carriers, 77% of whom were homosexual men and 62% of whom were HBeAg-positive, the annual rate of seroconversion to anti-HBe was less than 5% (Viola et al. 1981) . In a study from Taiwan in which there were no homosexual men, the annual seroconversion rate was approximately 17% (Liaw et al. 1983 ). The response rates of 11% for the homosexual men and 53% for the heterosexual men in our retrospective analysis are more than double these published spontaneous seroconversion rates (Novick et al. 1984b ).
An additional factor which complicates evaluation of antiviral therapy for the HBeAg-positive phase is spontaneous reactivation of chronic HBV infection. Two groups of investigators from the USA have reported patients who have spontaneously lost HBeAg, DNA polymerase and/or HBV-DNA, but several months later developed an exacerbation of their chronic liver disease manifested by sudden elevations of serum transaminases and reappearance of these viral markers (Davis et al. 1984 , Perrillo et al. 1984 .
Signs and symptoms of hepatic failure developed in some such patients. One group has noted an association of reactivation of HBV infection with male homosexuality (Perrillo et al. 1984 ). In addition, 2 patients have been described who lost HBeAg after treatment with ARA-AMP but several months later reverted to an HBeAgpositive state (Hoofnagle et al. 1984) . Reactivation of chronic HBV infection has not been seen in treated or untreated patients at the Royal Free Hospital. A possible explanation for its observation in the USA is that homosexual men there may have more profound immunological abnormalities than their counterparts in the UK, perhaps caused in part by a subclinical form of the acquired immune deficiency syndrome (AIDS) . In any event, these observations necessitate that patients who are considered to have responded to antiviral therapy be observed for a long period to ensure that reactivation does not occur.
In HBeAg-positive patients with a high level of viral replication, antiviral therapy could become the treatment of choice. The challenge to investigators in this field is to find the most effective drug, in the proper regimen, for each suibset of patients. Large clinical trials are needed for this purpose and are now in progress. It seems probable that the ultimate regimen will include both antiviral drugs and immune manipulation for the adequate elimination of hepatocytes containing replicating and integrated virus. The latter is essential if we are to deal with the problem of neoplasia as well as infectivity and inflammatory liver disease. 
